Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same

A method of preventing or treating chronic myeloid leukemia of a subject, the method comprising administering a compound of the following Chemical Formula I, a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or a combination thereof;

• and a tyrosine kinase inhibitor to the subject:
• wherein Ra is independently H, halo, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, OH, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —O—C3-6 cycloalkyl, NH2, —NH—C1-6 alkyl, —NH—C1-6 haloalkyl, —NH—C3-6 cycloalkyl, —S—C1-6 alkyl, —S—C1-6 haloalkyl, —S—C3-6 cycloalkyl, CN, or NO2;
• m is 0, 1, 2, 3 or 4;
• any one of A1 and A2 is N and the other is NR1, wherein R1 is H, OH, C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl;
• X is —NR2−, —O— or —S—, wherein R2 is H or C1-3 alkyl;
• Rb is each independently H, halo, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, —(CH2)q—OR3, —(CH2)q—NR3R4, —(CH2)q—SR3, —(CH2)q—NO2, —(CH2)q—CONHOH, —(CH2)q—CN, —(CH2)q—COR3, —(CH2)q—CO2R3, —(CH2)q—CONR3R4, —(CH2)q-tetrazole, —(CH2)q—CH═CH—CN, —(CH2)q—CH═CH—CO2R3, —(CH2)q—CH═CH—CONR3R4, —(CH2)q—CH═CH-tetrazole, —(CH2)q—NHCOR3, —(CH2)q—NHCO2R3, —(CH2)q—CONHSO2R3, —(CH2)q—NHSO2R3, —(CH2)q—C═C—CN, —(CH2)q—C═C—CO2R3, —(CH2)q—C═C—CONR3R4, —(CH2)q—C═C-tetrazole, —(CH2)q— SOR5, —(CH2)q-SO2R5, or —(CH2)r—(OR3)2, wherein R3 and R4 are each independently H, C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl, or taken together with the nitrogen atom bound thereto to form a mono-cyclic ring, for example, imidazole, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine;
• R5 is C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl;
• q is 0, 1, 2, 3, or 4;
• and r is 1, 2, 3, or 4;
• and
• n is 0, 1, 2, 3, 4 or 5.